Provided by Tiger Trade Technology Pte. Ltd.

BioAge Labs Inc.

16.15
-0.1000-0.62%
Post-market: 16.150.00000.00%16:10 EDT
Volume:313.89K
Turnover:5.13M
Market Cap:716.73M
PE:-7.20
High:17.12
Open:16.90
Low:16.04
Close:16.25
52wk High:24.00
52wk Low:2.88
Shares:44.38M
Float Shares:28.58M
Volume Ratio:0.37
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2432
EPS(LYR):-2.2432
ROE:-27.09%
ROA:-17.76%
PB:2.63
PE(LYR):-7.20

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel

Reuters
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital

Reuters
·
Jan 22

BUZZ-BioAge Labs edges down after stock sale hiked to $115 mln

Reuters
·
Jan 22

BRIEF-Bioage Announces Pricing Of Upsized $115 Million Public Offering

Reuters
·
Jan 22

Bioage Announces Pricing of Upsized $115.0 Million Public Offering

THOMSON REUTERS
·
Jan 22

BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies

Reuters
·
Jan 21

BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous

Reuters
·
Jan 21

BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating

TIPRANKS
·
Jan 21

BioAge Labs Proposes Public Offering Worth $75 Million

MT Newswires Live
·
Jan 21

BioAge Labs announces $75M common stock offering

TIPRANKS
·
Jan 21

Bioage Labs Inc - to Offer up to $75 Mln of Common Stock

THOMSON REUTERS
·
Jan 21

Bioage Announces Proposed Public Offering

THOMSON REUTERS
·
Jan 21

BioAge Labs management to meet with Piper Sandler

TIPRANKS
·
Jan 21

BioAge Labs: Early-Stage NLRP3 Opportunity in Ophthalmology and Cardiometabolic Disease Warrants Neutral ‘Hold’ Amid Long Clinical Timelines

TIPRANKS
·
Jan 21

BioAge Labs announces expansion of its BGE-102 development program

TIPRANKS
·
Jan 20

BioAge Labs Expands BGE-102 Program to Diabetic Macular Edema with Oral NLRP3 Inhibitor

Reuters
·
Jan 20

Bioage Labs Inc - Dme Trial Results Expected Mid-2027, Bge-102 Phase 2a Cardiovascular Trial Results Anticipated in 2H26

THOMSON REUTERS
·
Jan 20

Bioage Announces Indication Expansion for Oral Nlrp3 Inhibitor Bge-102, With Plans to Initiate Phase 1B/2a Proof-of-Concept Clinical Trial in Patients With Diabetic Macular Edema in Mid-2026

THOMSON REUTERS
·
Jan 20

BioAge Labs CEO Kristen Fortney Reports Disposal of Common Shares

Reuters
·
Jan 16

BioAge Labs, Inc. (BIOA) Gets a Buy from Citi

TIPRANKS
·
Jan 13